SWOG 1826-A Phase III, Randomized Study of Nivolumab (Opdivo) plus AVD or Brentuximab Vedotin (Adcetris) plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Start Date: January 06, 2020

IRB Number: https://clinicaltrials.gov/ct2/show/NCT03907488

Condition/Disease: Cancer - Lymphoma

Principal Investigator: Ding Wang, MD

Purpose of Research: Advanced classical Hodgkin lymphoma, advanced Hodgkin lymphoma, newly diagnosed Hodgkin lymphoma

Status: Accepting Participants

Phone: 313-844-7794

Filter Results